Analyst firms · Morgan Stanley · EW

Morgan Stanley EW price target and rating history

Edwards Lifesciences Corporation (EW) · Health Care

Morgan Stanley rates Edwards Lifesciences Corporation (EW) Equal-Weight with a $70 price target, as of its latest action on Oct 11, 2024. It has published 6 rating actions on EW since July 2021, including 0 upgrades and 0 downgrades. Across 7 firms with a EW price target in the last 12 months, the median target is $110.

Current rating
Equal-Weight
Price target
$70
Median target, all firms
$110
Actions on EW
6

Morgan Stanley price target on EW

$148$109$7020222023202420252026
Morgan Stanley price target on EW, each point a stated target, July 2021 to October 2024.

Every Morgan Stanley rating on EW

How other firms rate EW

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Robert W. BairdOutperform$116Nov 5, 2026
Truist SecuritiesBuy$113Nov 4, 2026
BarclaysOverweight$110Oct 7, 2026
UBSBuy$110Jul 28, 2026
Leerink PartnersOutperform$101Jul 24, 2026
Wolfe ResearchOutperform$92Apr 1, 2026
TD CowenBuy$97Jan 9, 2026

Questions about Morgan Stanley and EW

What is Morgan Stanley's price target for EW?
Morgan Stanley's latest stated price target for Edwards Lifesciences Corporation (EW) is $70, from its action on Oct 11, 2024.
What is Morgan Stanley's rating on EW?
Morgan Stanley rates EW Equal-Weight, a neutral rating, as of Oct 11, 2024.
When did Morgan Stanley last change its view on EW?
On Oct 11, 2024, Morgan Stanley resumes coverage at Equal-Weight, price target $70.
How does Morgan Stanley's EW target compare with other analysts?
Across 7 firms with a EW price target in the last 12 months, the median target is $110.

More EW rating histories

All Morgan Stanley ratingsEW news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.